Funder
Pharmaceutical Research and Manufacturers of America Foundation
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41:261–307.
2. Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1–10.
3. Dasari BVM, Hodson J, Nassir A, Widmer J, Isaac J, Mergentel H, et al. Variations in practice to therapeutic monitoring of tacrolimus following primary adult liver transplantation. Int J Organ Transplant Med. 2016;7:1–8.
4. Chang DH, Youn J-C, Dilibero D, Patel JK, Kobashigawa JA. Heart transplant immunosuppression strategies at cedars-sinai medical center. Int J Heart Fail. 2021;3:15–30.
5. Kamdem LK. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clinical Chemistry. 2005;51:1374–81.